首页> 外文期刊>Neurourology and urodynamics. >Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats.
【24h】

Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats.

机译:β(3)-肾上腺素受体刺激对清醒大鼠前列腺素E(2)诱导的膀胱机能亢进和心血管系统的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

AIMS: To investigate the effects of selective beta(2)- and selective beta(3)-adrenoceptor (AR) agonists on prostaglandin (PG) E(2)-induced bladder hyperactivity in conscious free-moving rats. METHODS: Female Sprague-Dawley rats were anesthetized for implantation of bladder, intravenous, and intra-arterial catheters. The effects of a beta(3)-AR agonist (CL316,243) on cystometric and cardiovascular parameters were assessed in conscious rats. Intravesical instillation of PGE(2) (20-60 microM, 6 mL/hr) in conscious rats produced a concentration-dependent increase in voiding frequency. RESULTS: In this model i.v. CL316,243 (beta(3)-AR agonist) reduced basal bladder pressure, increased micturition volume, and prolonged micturition interval in a dose-dependent manner, without affecting threshold pressure or micturition pressure. On the other hand, i.v. procaterol (beta(2)-AR agonist) did not counteract the bladder hyperactivity. Atropine (muscarinic antagonist) reduced micturition pressure and micturition volume, and shortened micturition interval. CL316,243 slightly decreased mean blood pressure and increased heart rate only when given at high doses (10 and 100 microg/kg, i.v.). In contrast, procaterol caused a significant decrease in mean blood pressure and a significant increase in heart rate. Atropine significantly increased heart rate. CONCLUSIONS: The present results clearly demonstrated that the beta(3)-AR agonist prolonged the micturition interval without producing significant cardiovascular side effects. The human detrusor, like the rat detrusor, relaxes on beta(3)-AR stimulation. Provided that these results are valid in humans, selective beta(3)-AR agonists might be clinically useful for controlling a certain type of bladder overactivity.
机译:目的:研究选择性β(2)-和选择性β(3)-肾上腺素能受体(AR)激动剂对有意识的自由运动大鼠前列腺素(PG)E(2)诱导的膀胱机能亢进的影响。方法:麻醉雌性Sprague-Dawley大鼠,植入膀胱,静脉和动脉内导管。在清醒大鼠中评估了β(3)-AR激动剂(CL316,243)对膀胱测量和心血管参数的影响。在清醒大鼠中膀胱内注射PGE(2)(20-60 microM,6 mL / hr)会导致排尿频率的浓度依赖性增加。结果:在此模型中CL316,243(β(3)-AR激动剂)以剂量依赖的方式降低了基础膀胱压力,增加了排尿量并延长了排尿间隔,而不会影响阈值压力或排尿压力。另一方面,i.v。丙卡特罗(β(2)-AR激动剂)不能抵消膀胱过度活动症。阿托品(毒蕈碱拮抗剂)降低排尿压力和排尿量,并缩短排尿间隔。 CL316,243仅在以大剂量(10和100微克/千克,静脉注射)给药时,平均血压会略微降低,而心率只会升高。相反,丙卡特罗引起平均血压的显着降低和心率的显着提高。阿托品明显增加心率。结论:目前的结果清楚地表明,β(3)-AR激动剂延长了排尿间隔,而没有产生明显的心血管副作用。像大鼠逼尿肌一样,人类逼尿肌在beta(3)-AR刺激下会放松。如果这些结果在人类中有效,则选择性β(3)-AR激动剂可能在临床上可用于控制某种类型的膀胱过度活动症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号